Entrar/Registro  
HOME SPANISH
 
Acta Pediátrica de México
   
MENU

Contents by Year, Volume and Issue

Table of Contents

General Information

Instructions for Authors

Message to Editor

Editorial Board






>Journals >Acta Pediátrica de México >Year 2013, Issue 6


Camacho MI, Yamazaki NMA
Treatment with intravenous gammaglobulin in pediatric patients with primary vasculitis
Acta Pediatr Mex 2013; 34 (6)

Language: Español
References: 27
Page: 358-363
PDF: 412.72 Kb.


Full text




ABSTRACT

Nowadays intravenous immunoglobulins have been used in different vasculitis with various results for each condition, being more recommended for its use in Kawasaki disease and ANCA-associated vasculitis. However, there is still no solid evidence to support its use in the entire group of these diseases. We present a review of the existing literature related to the use of intravenous immunoglobulin for the treatment of primary vasculitis in childhood.


Key words: Primary vascultis, intravenous gammaglobulin, children.


REFERENCIAS

  1. Eleftheriou D, Brogan PA. Vasculitis in children. Best Pract Res Clin Rheumatol. 2009;23:309-323.

  2. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheumatism. 2013;65:1-11.

  3. Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006;65:936-941.

  4. Imbach P, d’Appuso V, Hirt A, Rossi E, et al. High-dose intravenous gamma globulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;317:1228-1231.

  5. Tjon AS, Tha-In T, Metselaar HJ, van Gent R, van der Laan LJ, Groothuismink ZM, et al. Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells. Clin Exp Immunol. 2013. doi:10.1111/cei.12102.

  6. Zhu BH, Lu HT, Sun L, Zhang JM, Cao L, Jia HL, et al. A metaanalysis on the effect of corticosteroid therapy in Kawasaki disease. Eur J Pediatr. 2011.

  7. Yeo JS, Choi JW. Effectiveness of medium-dose intravenous immunoglobulin (1 g/kg) in the treatment of Kawasaki disease. Korean Circ J. 2010; 40:81-85.

  8. Oates-Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, Roman K, Dua JS, Flynn I. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2003;CD004000.

  9. Park HM, Lee DW, Hyun MC, Lee SB. Predictors of nonresponse to intravenous immunoglobulin therapy in Kawasaki disease. Korean J Pediatr. 2013;56:75-79.

  10. Hwang JY, Lee KY, Rhim JW, Youn YS, Oh JH, Han JW, et al. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease. Arch Dis Child. 2011;96:1088-1090.

  11. Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics. 2000;105:78.

  12. Yamazaki-Nakashimada MA, Espinosa-López M, Contreras VA Hernández-Bautista V, Espinosa-Rosales F. Espectro clínico de la enfermedad de Kawasaki. Alerg Asm Immun Ped. 2005;14:60-63.

  13. Yamazaki-Nakashimada MA, Espinosa-López M, Hernández- Bautista V, Espinosa-Padilla S, Espinosa-Rosales F. Catastrophic Kawasaki disease or juvenile Polyarteritis nodosa? Semin Arthritis Rheum. 2006;35:349-354.

  14. Jayne DR, Chapel H, Adu D, Misbah S, O’Donoghue D, Scott D, Lockwood CM. Intravenous immunoglobulin for ANCAassociated systemic vasculitis with persistent disease activity. QJM. 2000;93:433-439.

  15. Svetlicky N, Blank M, Zandman-Goddard G. The beneficial effects of intravenous immunoglobulin for antineutrophil cytoplasmic antibody-positive vasculitis. IMAJ 2012;14:568-569.

  16. Jayne DR, Chapel H, Adu D, Misbah S, O’Donoghue D, Scott D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. Q J Med 2000;93:433-439.

  17. Marie I, Miranda S, Girszyn N, Soubrane JC, Vandhuick T, Levesque H. Intravenous immunoglobulins as treatment of severe cutaneous polyarteritis nodosa. Intern Med J. 2012;42:459-462.

  18. Uziel Y, Silverman ED. Intravenous immunoglobulin therapy in a child with cutaneous polyarteritis nodosa. Clin Exp Rheumatol. 1998;16:187-189.

  19. Balbir-Gurman A, Nahir AM, Braun-Moscovici Y. Intravenous immunoglobulins in polyarteritis nodosa restricted to the limbs: case reports and review of the literature. Clin Exp Rheumatol. 2007;25:28-30.

  20. Gedalia A, Correa H, Kaiser M, Sorensen R. Case report: steroid sparing effect of intravenous gamma globulin in a child with necrotizing vasculitis. Am J Med Sci. 1995;309:226-228.

  21. Machet L, Vincent O, Machet MC, Barruet K, Vaillant L, Lorette G. Cutaneous periarteritis nodosa resistant to combined corticosteroids and immunosuppressive agents. Efficacy of treatment with intravenous immunoglobulins. Ann Dermatol Venereol. 1995;122:769-772.

  22. Kroiss M, Hohenleutner U, Gruss C, Glaessl A, Landthaler M, Stolz W. Transient and partial effect of high-dose intravenous immunoglobulin in polyarteritis nodosa. Dermatology. 2001;203:188-189.

  23. González-Fernández MA, García-Consuegra J. Polyarteritis nodosa resistant to conventional treatment in a pediatric patient. Ann Pharmacother. 2007;41:885-890.

  24. Berrón Pérez RD, Yamazaki-Nakashimada MA. Arteritis de Takayasu. En: Enfermedades autoinmunitarias en el niño. Alfil editorial. México 2007. p. 217-226.

  25. Jayne DR, Esnault VL, Lockwood CM. ANCA anti-idiotype antibodies and the treatment of systemic vasculitis with intravenous immunoglobulin. J Autoimmun. 1993;6:207-219.

  26. Zaffanello M, Brugnara M, Franchini M. Therapy for children with Henoch-Schönlein purpura nephritis: A systematic review. Scientific World Journal. 2007;7:20-30.

  27. Seider N, Beiran I, Scharf J, Miller B. Intravenous immunoglobulin therapy for resistant ocular Behçet’s disease. Br J Ophthalmol. 2001;85:1287-1288.






>Journals >Acta Pediátrica de México >Year 2013, Issue 6
 

· Journal Index 
· Links 






       
Copyright 2019